Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth
- PMID: 23624169
- PMCID: PMC3749874
- DOI: 10.1016/j.neuroimage.2013.04.048
Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth
Abstract
Background: Although it is well known that many clinical and genetic factors have been associated with beta-amyloid deposition, few studies have examined the interactions of such factors across different stages of Alzheimer's pathogenesis.
Methods: We used 18F-florbetapir F18 PET imaging to quantify neuritic beta-amyloid plaque density across four cortical regions in 602 elderly (55-94 years) subjects from the national ADNI biomarker study. The group comprised of 194 normal elderly, 212 early mild cognitive impairment [EMCI], 132 late mild cognitive impairment [LMCI], and 64 mild Alzheimer's (AD).
Findings: In a model incorporating multiple predictive factors, the effect of apolipoprotein E ε4 and diagnosis was significant on all four cortical regions. The highest signals were seen in cingulate followed by frontal and parietal with lowest signals in temporal lobe (p<0.0001). The effect of apolipoprotein E ε4 (Cohen's D 0.96) on beta-amyloid plaque density was approximately twice as large as the effect of a diagnosis of AD (Cohen's D 0.51) and thrice as large as the effect of a diagnosis of LMCI (Cohen's D 0.34) (p<0.0001). Surprisingly, ApoE ε4+ normal controls had greater mean plaque density across all cortical regions than ε4- EMCI and ε4- LMCI (p<0.0001, p=0.0009) and showed higher, though non-significant, mean value than ε4- AD patients (p<0.27). ApoE ε4+ EMCI and LMCI subjects had significantly greater mean plaque density across all cortical regions than ε4- AD patients (p<0.027, p<0.0001).
Interpretation: Neuritic amyloid plaque load across progressive clinical stages of AD varies strongly by ApoE4 genotype. These findings support the need for better pathology-based and supported diagnosis in routine practice. Our data also provides additional evidence for a temporal offset between amyloid deposition and clinically relevant symptoms.
Copyright © 2013 Elsevier Inc. All rights reserved.
Figures


Similar articles
-
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.Neurobiol Aging. 2013 Jan;34(1):1-12. doi: 10.1016/j.neurobiolaging.2012.04.017. Epub 2012 May 24. Neurobiol Aging. 2013. PMID: 22633529
-
18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.Neurobiol Aging. 2014 Sep;35(9):2096-106. doi: 10.1016/j.neurobiolaging.2014.03.006. Epub 2014 Mar 11. Neurobiol Aging. 2014. PMID: 24702820 Free PMC article.
-
Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.J Korean Med Sci. 2016 Feb;31(2):286-95. doi: 10.3346/jkms.2016.31.2.286. Epub 2016 Jan 13. J Korean Med Sci. 2016. PMID: 26839485 Free PMC article.
-
Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.IDrugs. 2010 Dec;13(12):890-9. IDrugs. 2010. PMID: 21154149 Review.
-
Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.Neuropsychol Rev. 2014 Sep;24(3):290-9. doi: 10.1007/s11065-014-9263-8. Epub 2014 Aug 22. Neuropsychol Rev. 2014. PMID: 25146994 Review.
Cited by
-
Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype.Brain. 2018 Jun 1;141(6):1828-1839. doi: 10.1093/brain/awy103. Brain. 2018. PMID: 29672664 Free PMC article.
-
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.Alzheimers Dement. 2015 Jul;11(7):865-84. doi: 10.1016/j.jalz.2015.04.005. Alzheimers Dement. 2015. PMID: 26194320 Free PMC article. Review.
-
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001. Alzheimers Dement. 2015. PMID: 26073027 Free PMC article. Review.
-
Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease.Biol Psychiatry. 2018 Feb 15;83(4):347-357. doi: 10.1016/j.biopsych.2017.03.003. Epub 2017 Mar 14. Biol Psychiatry. 2018. PMID: 28434655 Free PMC article. Review.
-
BFLCRM: A BAYESIAN FUNCTIONAL LINEAR COX REGRESSION MODEL FOR PREDICTING TIME TO CONVERSION TO ALZHEIMER'S DISEASE.Ann Appl Stat. 2015 Dec;9(4):2153-2178. doi: 10.1214/15-AOAS879. Ann Appl Stat. 2015. PMID: 26900412 Free PMC article.
References
-
- Bahar-Fuchs A, Villemagne V, et al. Prediction of Amyloid-beta Pathology in Amnestic Mild Cognitive Impairment with Neuropsychological Tests. J Alzheimers Dis 2012 - PubMed
-
- Barthel H, Gertz HJ, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424–35. - PubMed
-
- Chetelat G, Villemagne VL, et al. Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer’s disease. Neurodegener Dis. 2012;10(1–4):141–4. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous